RBM4 and ovarian carcinoma: However, our study showed that RBM4 protein expression levels were generally higher (43.8%) than Wang’s study (19.0%) in cancers, and the reasons may be as follows: 1) different secondary antibodies were used: Abcam company (Wang study) vs Dako company (our study); 2) different research objects: ovarian cancer, non small cell lung cancer and pancreatic cancer (Wang study) vs gastric cancer (our study), as the expression of RBM4 protein may not be the same in different tumors.